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Mitochondrial proton leakMuscle insulin resistance is linked to oxidative stress and decreased mitochondrial function. However, the exact
cause of muscle insulin resistance is still unknown. Since offspring of patients with type 2 diabetes mellitus
(T2DM) are susceptible to developing insulin resistance, they are ideal for studying the early development of
insulin resistance. By using primary muscle cells derived from obese non-diabetic subjects with (FH+) or with-
out (FH−) a family history of T2DM, we aimed to better understand the link between mitochondrial function,
oxidative stress, and muscle insulin resistance. Insulin-stimulated glucose uptake and glycogen synthesis were
normal in FH+myotubes. Resting oxygen consumption ratewas not different between groups. However, proton
leak was higher in FH+ myotubes. This was associated with lower ATP content and decreased mitochondrial
membrane potential in FH+ myotubes. Surprisingly, mtDNA content was higher in FH+ myotubes. Oxidative
stress level was not different between FH+ and FH− groups. Reactive oxygen species content was lower in
FH+ myotubes when differentiated in high glucose/insulin (25 mM/150 pM), which could be due to higher
oxidative stress defenses (SOD2 expression and uncoupled respiration). The increased antioxidant defenses
and mtDNA content in FH+ myotubes suggest the existence of compensatory mechanisms, which may provi-
sionally prevent the development of insulin resistance.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Type 2 diabetes mellitus (T2DM) prevalence worldwide was esti-
mated to be 171 million in 2000 and is predicted to increase to
366 million by 2030 [1]. One of the hallmarks of T2DM is insulin resis-
tance. Due to its mass (40% of total body weight in healthy adults),
skeletal muscle becomes the primary site of insulin resistance during
T2DM development [2]. The heritability of T2DM has been estimated
to be over 60% based on studies of monozygotic twins, with the her-
itability of certain diabetes-related traits to be as high as 80% [3,4].; COX, cytochrome C oxidase;
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l rights reserved.Furthermore, offspring of type 2 diabetic patients have a signiﬁcantly
increased risk of developing diabetes during their lifetime [5].
The exact cause of muscle insulin resistance is not yet known, but it
has been suggested that ectopic lipid accumulation (e.g., acylcarnitines,
diacylglycerol, ceramides) within the skeletal muscle, due to a decrease
in mitochondrial function or number [6–8], affects the insulin signaling
pathway, leading to a decrease in insulin-stimulated glucose uptake in
muscle [9–11]. Since young, lean, insulin-resistant offspring of patients
with T2DM also present defects in mitochondrial function, before the
development of T2DM [6], it was thought that mitochondrial dysfunc-
tion was the primary event leading to T2DM. However, the subjects
studied in this study were already insulin resistant, so it was not possi-
ble to prove a cause-and-effect relationship between defects in mito-
chondrial function and/ormitochondrial content and insulin resistance.
In a more recent study, mitochondrial dysfunction in rodents was
shown not to be the cause of insulin resistance, but rather the conse-
quence of oxidative stress that develops in response to lipid overload
[12]. Other studies have concluded that increased oxidative stress could
be the cause of muscle insulin resistance development [13,14]. Oxida-
tive stress results from an excess of reactive oxygen species (ROS) pro-
duction over antioxidative defenses. How ROS induce insulin resistance
in the skeletal muscle is still unclear, but it seems that excess ROS can
1625C. Aguer et al. / Biochimica et Biophysica Acta 1832 (2013) 1624–1633induce phosphorylation of IRS1 on its serine residues, directly or indi-
rectly through the activation of JNK (c-Jun N-terminal kinase) or IκKβ
(inhibitor of NF-κB kinase), which leads to an inhibition of the insulin
signaling pathway (for review, see: [15]).
Primary myotubes derived from T2DM patients have been shown
to display the majority of metabolic defects found in vivo in the skel-
etal muscle of T2DM patients: decreased insulin-stimulated glucose
uptake and glycogen synthesis [16–18] and decrease fatty acid oxida-
tion [19–21]. This in vitro muscle system provides an attractive model
in which mitochondrial function and oxidative stress can be evaluat-
ed apart from the systemic inﬂuences of the in vivo environment.
In this context, our aim was to better understand the link between
muscle mitochondrial function, oxidative stress, and insulin resis-
tance development by using human primary muscle cells derived
from obese non-diabetic, insulin sensitive subjects with a family his-
tory of T2DM (FH+), as a population at risk to develop muscle insulin
resistance. Our initial hypotheses were that FH+myotubes will (1) be
insulin sensitive, (2) show a decreased mitochondrial content coupled
or not to a decreased mitochondrial function, (3) have higher suscepti-
bility to oxidative stress.
2. Research design and methods
2.1. Participants
Six obese, non-diabetic women with a ﬁrst degree relative with
T2DM (FH+) were recruited. The 6 control participants (FH−) were
matched for sex, age, BMI, physical activity (assessed by the Interna-
tional Physical Activity Questionnaire (IPAQ: 7-day)) and insulin
sensitivity (assessed by the HOMA index). The characteristics of the
participants are described in Table 1. All participants gave informed
consent and the experimental protocol was approved by the Human
Research Ethics Committees of the Ottawa Hospital and the University
of Ottawa Heart Institute.
2.2. Anthropometric, blood chemistry and indirect
calorimetry measurements
All measurements were obtained after completion of the Ottawa
Hospital Weight Management Program and a period of weight stabi-
lization of at least 4 weeks. All measurements were made after an
overnight fast. Body mass and body composition were assessed using
bioelectrical impedance analysis with a Tanita TBF-410GS body compo-
sition analyzer (Arlington Heights, IL). Fasting plasma glucose, insulin,
triacylglycerol, total cholesterol, LDL-cholesterol, HDL-cholesterol,Table 1
Characteristics of the participants.
FH− (n = 6) FH+ (n = 6)
Age (years) 50.0 ± 3.7 50.8 ± 2.7
BMI 33.2 ± 1.3 32.7 ± 1.6
Waist (cm) 100.5 ± 3.6 93.6 ± 4.1
Hips (cm) 119.4 ± 2.5 117.7 ± 3.2
Waist/hips ratio 0.84 ± 0.02 0.79 ± 0.02
Fat mass (kg) 41.3 ± 1.8 37.3 ± 3.6
% fat 45.9 ± 0.7 45.0 ± 1.9
FFM (kg) 51.0 ± 1.2 49.6 ± 2.1
Fasting blood glucose (mM) 5.1 ± 0.1 5.4 ± 0.2
Fasting plasma insulin (pM) 48.0 ± 8.9 54.4 ± 18.3
HOMA index 1.2 ± 0.3 1.9 ± 0.7
Fasting plasma total cholesterol (mM) 6.0 ± 0.4 5.7 ± 0.4
Fasting plasma HDL-cholesterol (mM) 1.6 ± 0.1 1.6 ± 0.2
Fasting plasma LDL-cholesterol (mM) 3.7 ± 0.4 3.6 ± 0.3
Fasting plasma triglycerides (mM) 1.5 ± 0.4 1.1 ± 0.1
HbA1C 0.054 ± 0.0008 0.053 ± 0.0004
Resting metabolic rate (kcal/day) 1536.4 ± 78.3 1509.4 ± 71.5
Resting metabolic rate (kcal/kg FFM/day) 29.8 ± 1.5 31.4 ± 2.4
Resting respiratory quotient 0.88 ± 0.03 0.89 ± 0.03HbA1C were measured at rest. Fasting plasma glucose, HbA1c, total
cholesterol, HDL-cholesterol and triglycerides were measured on
the Beckman Coulter LX 20 automated chemistry analyzer using
manufacturer's reagents (Beckman Coulter Inc., Brea California).
LDL-cholesterol was calculated using the Friedewald equation.
Fasting plasma insulin was measured on the Beckman Coulter Dxi
immunoassay analyzer using the manufacturer's reagents (Beckman
Coulter Inc., Brea California).
Resting metabolic rate (RMR) and respiratory quotient (RQ) were
determined for 30 min by indirect calorimetry using a MOXUS Mod-
ular VO2 System (AEI Technologies Inc., Naperville, IL). To eliminate
effects of subject habituation to the testing procedure, the respiratory
measurements during the ﬁrst half of the test were not included in
the calculations. Oxygen consumption rates (VO2) and carbon dioxide
production rates (VCO2) were used to calculate RMR using the Weir
equation (RMR = [(1.106 × RQ) + 3.941] × VO2) [22] and to calculate
RQ (RQ = VCO2/VO2).
2.3. Muscle biopsy and primary human muscle cell culture
Biopsies of the vastus lateralis were obtained under local anesthe-
sia, using a 5 mm Bergstrom needle (Opitek International, Glostrup,
Denmark) as described previously by Costford et al. [23]. Subjects
were fasted for 12 h and refrained from physical activity for three
days prior to the biopsy. Forty milligrams of the muscle biopsy was
processed for satellite cell isolation [23]. Muscle satellite cells were
isolated at ~80% conﬂuency using an immuno-based magnetic sorting
technique as previously described [23]. Isolated primary muscle cells
were grown in Ham's F-10 (6.11 mM glucose) (Gibco, Burlington, ON,
Canada) supplemented with 12.5% FBS, 1 μM dexamethazone, 10 ng/ml
EGF, 25 pM insulin, 1× antibiotic–antimycotic and 2.5 μg/ml gentamycin
(growth medium, GM) to ~90% conﬂuency prior to differentiation in
either low glucose and low insulin DMEM (LGI) (5.5 mM glucose,
supplemented with 1 mM sodium pyruvate, 25 pM insulin, 2% horse
serum, 1× antibiotic–antimycotic and 2.5 μg/ml gentamycin) or high glu-
cose and high insulin DMEM (HGI) (25 mM glucose, supplemented with
1 mM sodium pyruvate, 150 pM insulin, 2% horse serum, 1% antibiotic–
antimycotic and 2.5 μg/ml gentamycin) for 7 days prior to experimenta-
tion. LGI differentiationmediummimics healthy fasting values of glucose
and insulin, whereas HGI differentiation medium mimics diabetic post-
prandial values of glucose and insulin.
2.4. Myotube glucose uptake
100,000 cells per well were plated in a 24-well plate. On day 6
of differentiation, myotubes were serum-starved for 16 h (differenti-
ation media (LGI or HGI) without horse serum). Myotubes were
then incubated in glucose-free DMEM ±100 nM insulin or ±5 μM
cytocholasin B (to determine non-speciﬁc glucose uptake) for 10 min
and then incubated in 0.25 μCi/well [3H]2-deoxyglucose and 100 μM
cold 2-deoxyglucose, as in [24].
2.5. Myotube glycogen synthesis
100,000 cells per well were plated in a 24-well plate. On day 6 of
differentiation, myotubes were serum-starved for 16 h (differentia-
tion media (LGI or HGI) without horse serum). Myotubes were incu-
bated in glucose-free DMEM for 1.5 h and then incubated in 0.5 μCi/
well [3H]2-deoxyglucose and 1 mM glucose ±100 nM insulin for
3 h. Myotubes were then washed 3 times with cold PBS and lysed
in 30% KOH. Samples were incubated in the presence of 2 mg/ml
glycogen for 20 min at 80 °C. Glycogen was precipitated with 100%
ethanol by 10,000 rpm centrifugation at 4 °C for 20 min. The pellet
was washed once with 70% ethanol and then dissolved in 500 μl
H2O. 400 μl were placed in a scintillation vial, and 5 ml of scintillation
1626 C. Aguer et al. / Biochimica et Biophysica Acta 1832 (2013) 1624–1633ﬂuid was added. Protein content was measured in parallel wells, with
the same number of cells and identical incubations.
2.6. Myotube substrate storage
Triglyceride content was measured in myotubes treated with and
without 400 μM oleate for the last 16 h of differentiation, using a kit
(L-Type TG H; Wako, Richmond, VA, USA) as previously described
[23]. Myotube glycogen content was measured as previously described
[23].
2.7. Extracellular ﬂux (XF) analysis of cellular metabolic characteristics
20,000 cells per well were plated in an XF24-well plate (Seahorse
Bioscience Inc., North Billerica, MA, USA). Myotubes were incubated
for 45 min at 37 °C at ambient CO2 in HCO3-free DMEM (pH 7.4)
containing 4 mM glutamine, 1 mM pyruvate and 5 mM glucose or
25 mM glucose. Oxygen consumption rates (OCR) were determined
in situ using a Seahorse extracellular ﬂux analyzer as described in
[25]. After baseline OCR measurement, state 4 OCR, maximal OCR
and extramitochondrial OCR were determined by treating myotubes
with oligomycin (600 ng/ml), FCCP (1 μM) and antimycin A (4 μM)
(all from Sigma-Aldrich, Oakville, ON, Canada), respectively. For
Fig. 3F, we estimated UCP3 (uncoupling protein 3) (and possibly
also ANT (adenine nuceotide translocase)) dependent protein leak
activity by measuring the percentage of resting OCR inhibition after
diamide treatment. After resting OCR measurement, diamide was
injected (ﬁnal concentration: 100 μM) and OCR was measured after
an 8 min waiting period. Vehicle was injected in half the wells as a
negative control. Myotubes were then collected for determinations
of protein content (Bradford assay). Mitochondrial OCR (resting,
oligomycin or FCCP OCR) are reported after the subtraction of OCR
in the presence of antimycin (i.e., non-mitochondrial oxygen con-
sumption) and expressed per μg of total cellular protein.
2.8. Western blots
Cell lysates were quantiﬁed for protein content and 30 μg of protein
were separated by 10 or 12% SDS-polyacrylamide gel electrophoresis
and then transferred to a nitrocellulose membrane. The following
primary antibodies were used: polyclonal anti-UCP3 (Abcam Inc.,
Cambridge, MA, USA), anti-SOD2 (maganese superoxide dismutase)
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-β-actin (Cell
Signaling Technologies, Pickering, ON, Canada), diluted 1/1000;monoclo-
nal anti-α-tubulin (Sigma-Aldrich, Oakville, ON, Canada), diluted 1/6000;
and total OXPHOS human antibody cocktail (Abcam Inc., Cambridge, MA,
USA), diluted 1/400. The secondary antibodies were anti-mouse and
anti-rabbit antibodies coupled to horseradish peroxidase. Proteins
were visualized using an enhanced luminescent reagent and ex-
posed to autoradiograph ﬁlm. α-Tubulin was used as a loading con-
trol. Expression of proteins was quantiﬁed by density analysis using
ImageJ Launcher Software.
2.9. ATP assay
ATP content in myotubes was assessed in the resting state using
the StayBrite ATP assay kit as described by the company (BioVision
Inc., Mountain View, CA, USA).
2.10. Human genomic and mitochondrial DNA isolation
Genomic and mitochondrial DNA was isolated using Qiagen blood
and tissue kit (cat. 69506). Brieﬂy, 200 μl DPBS was added to each
60 mm plate; cells were scraped and transferred to an Eppendorf
tube followed by the addition of 200 μl lysis buffer (AL) and 20 μl
proteinase K solution. Samples were treated according to protocol(except 400 μl ethanol was added at step 6) and eluted in 100 μl AE
buffer (10 mM Tris.Cl, 0.5 mM EDTA pH 9.0), 5 min RT followed by
1 min at 8000 rpm. DNA was measured using a Nanodrop 1000.
2.11. QPCR
DNA samples were diluted to 2.5 ng/μl in water and 4 μl (10 ng)
used for each QPCR reaction. Singleplex QPCR was performed using
an ABI 7500 Fast and Taqman assays for 12S and 18S RNA (Assay
Hs02596859_g1 and Hs99999901_s1). Brieﬂy, 4 μl (10 ng) DNA, 5 μl
2× Taqman Fast Universal Mastermix (Life Technologies Corporation
4352042), 0.5 μl Taqman assay and 0.5 μl water were mixed and the
reactions carried out in triplicate in a 96 well optical reaction plate.
Standard ABI 7500 Fast PCR conditions were used. Data from 2 plates
were combined and analyzed using ABI software.
2.12. Activity assays for citrate synthase (CS) and cytochrome C oxidase
(COX)
Intactmitochondriawere isolatedusing akit (MITOISO; Sigma-Aldrich,
Oakville, ON, Canada). CS activitywas assayed in lysedmitochondria using
akit (CSO720; Sigma-Aldrich, Oakville, ON, Canada)with 0.5 mMoxaloac-
etate, 0.3 mM acetyl-CoA, 0.1 mM of 5, 5′-dithiobis 2-nitro-benzoic acid.
Enzyme activity was monitored by recording the changes in absorbance
at 412 nm over 1.5 min. COX activity was measured in intact mitochon-
dria using a kit (Cytocox1; Sigma-Aldrich, Oakville, ON, Canada)
based on the decrease in absorbance over 3 min at 550 nm of
ferrocytochrome C caused by its oxidation to ferricytochrome C by
COX. Enzyme activities were normalized to protein content.
2.13. Mitochondrial membrane potential
An analysis of mitochondrial membrane potential was performed
using tetramethylrhodamine ethyl ester (TMRE), a ﬂuorescent dye
whose ﬂuorescence is quenched when accumulated in mitochondria
[26]. Myotubes were incubated at 37 °C for 10 min with 175 nM
TMRE in either low glucose-PBS (5.5 mM glucose, 4 mM L-glutamine
and 1 mM sodium pyruvate) or high glucose-PBS (25 mM glucose,
4 mM L-glutamine and 1 mM sodium pyruvate). Fluorescence was
read at 37 °C (excitation = 544 nm, emission = 590 nm). Cells were
then treated with 95 μl of low glucose assay buffer (vehicle control),
74 μMoligomycin, or 11 μMFCCP, and read once again for ﬂuorescence
within 5 min. Myotubes were then collected for determinations of pro-
tein content (Bradford assay). Sincemitochondrial membrane potential
wasmeasured using TMRE in the quenchmode, results are presented as
1/(change in ﬂuorescence normalized to protein content). A higher
value in Fig. 5A represents higher mitochondrial membrane potential.
2.14. Reactive oxygen species
ROS content of myotubes was measured in the resting state using
the DCFH-DA (2′,7′-dichlorﬂuorescein-diacetate) assay, as in [24].
Myotubes were solubilized in 50 μl 0.05 M NaOH, and protein was
quantiﬁed by a Bradford assay.
2.15. GSH and GSSG
Following 7 days of differentiation, cells were lifted, washed twice
with PBS, lysed in PBS containing 1% (w/v) perchloric acid, vortexed
and incubated on ice for 10 min. Cell lysates were then centrifuged
for 10 min at 12,000 g to remove precipitation. Samples were
injected into an Agilent 1100 Series HPLC equipped with a Pursuit
C18 column (150 × 4.6 mm, Agilent Technologies, Santa Clara, CA,
USA) at a ﬂow rate of 1 ml/min. The mobile phase consisted of 0.1%
triﬂuoroacetic acid/HPLC grade methanol (90:10) in MiliQ H2O [27].
Reduced and oxidized glutathione (GSH and GSSG, respectively)
1627C. Aguer et al. / Biochimica et Biophysica Acta 1832 (2013) 1624–1633were detected with an Agilent UV–visible variable wavelength set to
215 nm. Absolute amounts of GSH and GSSG were determined by
calculating the area under the curve for GSH and GSSG peaks on the
chromatograph using Agilent Chemstation software and applied to
GSH and GSSG standard curves. GSH and GSSG values were normalized
to protein content.
2.16. Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were
performed using Statview 5.0 (SAS Institute Inc., Cary, NC, USA).
2-way ANOVAs with Fisher's protected least signiﬁcant difference
(PLSD) post-hoc test were used to assess statistical differences.
P b 0.05 was considered to be signiﬁcant.
3. Results
3.1. Subject characteristics
Subject characteristics are shown in Table 1. FH− and FH+ par-
ticipants did not show difference for age, BMI, waist/hip ratio, fat
mass (absolute value and % of total bodyweight), fasting plasma insulin
and glucose concentration, HOMA index, fasting cholesterol levels
(total, HDL, LDL), fasting plasma triglycerides and HbA1c. Resting met-
abolic rate expressed as whole body resting metabolic rate (kcal/day)
or per kg of fat free mass, was not signiﬁcantly different between
FH− and FH+ subjects. Respiratory quotient at rest was also similar
between FH− and FH+ subjects.
3.2. FH+ myotubes are not insulin resistant
Glucose uptake and glycogen synthesis were measured in
myotubes differentiated in LGI or HGI, in the basal state and after400
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To determine mitochondrial function, we measured oxygen con-
sumption rate (OCR) in myotubes differentiated in LGI and HGI. Rest-
ing OCR was not signiﬁcantly different between FH− and FH+
myotubes, or between the differentiation conditions (Fig. 3A). How-
ever, proton leak (state 4 respiration) measured in the presence of
the ATP synthase inhibitor, oligomycin, was signiﬁcantly higher in
FH+myotubes compared to FH−myotubes (p b 0.001, group effect)
with no difference between the differentiation conditions (Fig. 3B).
Similarly, the state 4 OCR/resting OCR ratio was signiﬁcantly higher in
FH+ myotubes compared to FH− myotubes, showing that a higher
proportion of resting respiration was associated with uncoupled respi-
ration in FH+ myotubes compared to FH− myotubes (p b 0.001,
group effect, Fig. 3C). Maximal respiration, measured in the presence
of FCCP, was not different between groups or between the differentia-
tion conditions (Fig. 3D). Non-mitochondrial OCR (OCR measured
after complex III inhibition by antimycin) was lower in FH+ compared
to FH− myotubes (p = 0.02, group effect, data not shown), but this
difference was no longer signiﬁcant when LGI and HGI conditions
were analyzed independently (post-hoc test). To determine if the
higher uncoupled respiration in FH+ myotubes was the result of a
higher level of the only uncoupling protein in skeletal muscle,
UCP3, we measured UCP3 level by Western blot. UCP3 protein
level was not different between FH− and FH+ myotubes, and
UCP3 protein level was not affected by the differentiation conditions
(Fig. 3E). We then estimated UCP3 (and possibly also ANT) depen-
dent proton leak activity by measuring the percentage of resting
OCR inhibition after diamide treatment. Diamide has been shown
to inhibit UCP3 activity by glutathionylation [29]. However, the per-
centage of resting OCR inhibition by diamide was not signiﬁcantly
different between FH− and FH+ myotubes (Fig. 3F), suggesting
that the higher proton leak in FH+ myotubes was not the result of
increased UCP3 activity.B
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FH− and FH+myotubes differentiated for 7 days in LGI or HGI. N = 5–6. B and C: Citrate s
from FH− and FH+ myotubes differentiated for 7 days in LGI or HGI. N = 5–6, each meas
respiratory chain complexes (I–V, complex V = ATP synthase) in FH− and FH+ myotube
mitochondria were used as a positive control. Right panel: quantiﬁcation of complexes I–V3.5. FH+ myotubes show increased mtDNA content
Myotubes' mitochondrial content was determined as mitochon-
drial DNA (mtDNA). Interestingly, mtDNA content was signiﬁcantly
higher in FH+ myotubes compared to FH− myotubes in both LGI
and HGI conditions (p = 0.01, group effect, Fig. 4A). The differentia-
tion conditions did not affect mitochondrial content. We then deter-
mined whether key mitochondrial enzyme activities were different
per mitochondrial protein between groups, by measuring citrate
synthase and cytochrome C oxidase activities in isolated mitochon-
dria. These enzyme activities were not signiﬁcantly different between
FH− and FH+ myotubes (Fig. 4B and C) and were not signiﬁcantly
affected by the differentiation conditions, even if COX activity tended
to be higher when FH− cells were differentiated in HGI compared to
LGI (Fig. 4C). In order to conﬁrm the increased mitochondrial content
seen at mtDNA level in FH+ myotubes compared to FH− myotubes,
we measured the expression of proteins representing the 5 mito-
chondrial respiratory chain complexes. However, the expression of
these mitochondrial proteins was not signiﬁcantly increased in FH+
compared to FH− myotubes (Fig. 4D).
3.6. FH+ myotubes have lower mitochondrial membrane potential and
ATP content
An increase in proton leak should result in a decrease in mito-
chondrial membrane potential. State 4 membrane potential was sig-
niﬁcantly lower in FH+ myotubes compared to FH− myotubes
differentiated in LGI or HGI (p b 0.05, group effect, Fig. 5A). FCCP
was used as a positive control: FCCP, by inducing proton leak, de-
creased mitochondrial membrane potential (Fig. 5A and B). Since
resting OCR was not different between FH− and FH+ myotubes
(Fig. 5A), but uncoupled respiration (state 4 OCR) was higher in
FH+ than FH− myotubes (Fig. 3B and C), ATP synthesis should the-
oretically be lower in FH+ compared to FH− myotubes. We thusHGI
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1630 C. Aguer et al. / Biochimica et Biophysica Acta 1832 (2013) 1624–1633measured the ATP content in myotubes differentiated in LGI or HGI.
ATP content was signiﬁcantly lower in FH+ myotubes compared to
FH− myotubes (p b 0.001, group effect, Fig. 5B). The differentiation
conditions did not affect signiﬁcantly ATP content (Fig. 5B).
3.7. FH+myotubes show a lower ROS content in high glucose/high insulin
condition and higher SOD2 expression
ROS content was measured in myotubes differentiated in LGI and
HGI. Interestingly, ROS content was not signiﬁcantly different be-
tween FH− and FH+ myotubes when differentiated in LGI, but was
signiﬁcantly lower in FH+ myotubes compared to FH− myotubes
when differentiated in HGI (post-hoc test: p b 0.05, Fig. 6A). The
HGI condition is known to induce an increased production of ROS
[23]. FH− myotubes showed a trend for increased ROS when differ-
entiated in HGI compared to LGI. However, HGI condition did not
affect ROS content in FH+myotubes. We then measured protein car-
bonyl content in myotubes differentiated in LGI or HGI, as a marker of
oxidative stress. No signiﬁcant differences were noticed between
FH− and FH+ myotubes, as well as between the different differenti-
ation conditions (Fig. 6B). We then measured protein levels of man-
ganese superoxide dismutase (MnSOD or SOD2), the mitochondrial
enzyme that catalyzes the conversion of superoxide (O2•−) into hy-
drogen peroxide (H2O2) and oxygen (O2). Interestingly, SOD2 tended
to be higher in FH+ myotubes compared to FH− myotubes (p =
0.058, group effect, Fig. 6C). We also measured the reduced and oxi-
dized forms of glutathione (GSH and GSSG, respectively). A low
value of the 2GSH/GSSG ratio is an indicator of increased risk for ox-
idative stress [30]. Indeed, GSH plays a major role in the defense
against oxidative stress. When oxidized, 2 GSH molecules dimerize
to form GSSG. GSH content¸ and the 2GSH/GSSG ratio tended to be
higher in FH+ compared to FH− myotubes, especially in the HGI
condition, but it did not reach signiﬁcance due to high variability be-
tween FH+ myotubes (Fig. 6D, left and right panel, respectively).
GSSG content was similar between groups (Fig. 6D, center panel).
4. Discussion
The development of insulin resistance in muscle has been linked
to mitochondrial dysfunction and/or increased oxidative stress. In
the present study, we used primary myotubes derived from obese, in-
sulin sensitive offspring of T2DM patients (FH+), a population at risk
for insulin resistance, to determine links between mitochondrial dys-
function, oxidative stress and insulin resistance. Despite the small
number of study subjects, we were able to detect robust and intriguing
differences between study groups.Group effect for oligomycin: p<0.05
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Fig. 5. Decreased mitochondrial membrane potential and ATP content in myotubes derived f
potential measured using the TMRE method in FH− and FH+ myotubes differentiated fo
conditions (no treatment), after oligomycin treatment (ATP synthase inhibition) and aft
B: ATP content measured in resting conditions in FH− and FH+ myotubes differentiated fPrevious studies showed that lean offspring of T2DM patients dis-
play decreased mitochondrial number and impaired mitochondrial
activity [6,31–33], suggesting that mitochondrial dysfunction is one
of the ﬁrst events leading to muscle insulin resistance. It has been re-
cently suggested that the decreased mitochondrial content in off-
spring of those with type 2 diabetes was the result, at least in part,
to a decrease in skeletal muscle lipoprotein lipase activity, resulting
in decreased PPARγ activation [34]. However, since these subjects
were already insulin resistant, it was not possible to prove a cause-
and-effect relationship between defects in mitochondrial activity
and/or content and insulin resistance.
In the present study, offspring of T2DM patients were not insulin
resistant, as assessed at the whole body level by the HOMA index,
as well as in muscle cells in vitro by the measurement of insulin-
stimulated glucose uptake and glycogen synthesis. Interestingly, FH+
myotubes showed increased mtDNA content when compared to
myotubes derived from control subjects matched for age, sex, adiposity,
activity and insulin sensitivity. However, mitochondrial OXPHOS pro-
teins (complexes I–V) were not signiﬁcantly different between groups.
Thus, it is not clear if mitochondrial content was increased in FH+
myotubes. CS and COX activities, two key enzymes of the TCA cycle
and respiratory chain, respectively, were not different between FH+
and FH− isolated mitochondria, suggesting that mitochondrial activity
was not affected in FH+myotubes. However, consistent with the ~30%
decreased ATP content measured in skeletal muscle of lean offspring of
patients with type 2 diabetes [31], ATP content was signiﬁcantly de-
creased in FH+ myotubes whereas resting OCR was similar between
groups, suggesting an uncoupling between oxygen consumption and
ATP production in these myotubes. Indeed, OCR after the addition of
oligomycin, a measure of proton leak, was signiﬁcantly higher in FH+
compared to FH− myotubes. Furthermore, mitochondrial membrane
potential was signiﬁcantly lower in FH+ myotubes, consistent with a
higher proton leak. It thus seems that even if resting oxygen consump-
tion, and CS and COX activities measured in isolatedmitochondriawere
not affected in FH+myotubes, these myotubes were not able to main-
tain their ATP content due to increased proton leak. The expression of
UCP3 however was not affected in FH+ myotubes compared to FH−
myotubes. It is known that UCP3 is controlled by glutathionylation
[29]. In this study we used the glutathionylation catalyst, diamide,
to determine if diamide-sensitive proton leak was different between
groups. We did not detect differences; however, glutathionylation
may have caused inhibition of ANT or other mitochondrial proteins af-
fecting leak. Further studies are thus needed to determine the altered
mechanisms leading to this increased proton leak in FH+ myotubes.
It has been suggested that muscle insulin resistance, as well as
muscle mitochondrial dysfunction, were the result of the oxidative
stress that develops during a lipid or energy overload [12]. In ourB
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method in FH− and FH+ myotubes differentiated for 7 days in LGI or HGI. N = 6, each measurement done in 5 replicates. *, p b 0.05: FH+ vs. FH−. B. Left panel: representative
Western blot of protein carbonyls measured using the oxyblot kit in FH− and FH+ myotubes differentiated for 7 days in LGI or HGI. The Ponceau staining was used as a loading
control. Right panel: quantiﬁcation of protein carbonyls by density analysis. N = 3–4. C. Top panel: representative Western blot of SOD2 expression measured in FH− and FH+
myotubes differentiated in LGI or HGI for 7 days. α-Tubulin was used as a loading control. Right panel: quantiﬁcation of SOD2 expression by density analysis. N = 5. D. GSH
(left panel), GSSG (center panel) and 2GSH/GSSG ratio (right panel) measured in FH− and FH+ myotubes differentiated in LGI or HGI for 7 days. N = 5.
1631C. Aguer et al. / Biochimica et Biophysica Acta 1832 (2013) 1624–1633model, FH+ myotubes did not show any increased oxidative stress,
as measured by protein carbonyls and ROS content in FH+myotubes
was not different from that in FH− myotubes when differentiated in
LGI. Surprisingly, when challenged with a high glucose/high insulin
medium, ROS levels tended to increase in FH− myotubes whereas
FH+myotubes did not show any response to HGI conditions, leading
to a signiﬁcant difference in ROS content between FH− and FH+
myotubes in those conditions. Our results of lower ROS content in
FH+ myotubes are in line with the lower ROS production found in
myotubes from T2DM patients [35]. Interestingly, other studies sug-
gested that increased ROS formation may prevent the development of
insulin resistance [36–39]. It is thus possible that the increased ROS pro-
duction (as seen in FH− myotubes only) “prevents” the development
of insulin resistance, whereas, individuals who cannot increase their
ROS production (as seen in FH+myotubes)will (likely) develop insulin
resistance. Unfortunately, this concept cannot be fully elucidated in iso-
lated myotubes, thus further research is needed.
Interestingly, oxidative stress defenses (SOD2 expression and pro-
ton leak) were also higher in FH+ compared to FH−myotubes. GSH
content and GSH/GSSG also tended to be higher in FH+ myotubes,
but the variability between cell lines was too high for this to reachstatistical signiﬁcance. SOD2 is one of the major antioxidative en-
zymes in mitochondria. Mitochondrial proton leak, by decreasing mi-
tochondrial membrane potential, can also decrease ROS production
[40]. GSH is an antioxidative free-radical scavenging molecule, and
depletion in GSH increases susceptibility to oxidative stress [30]. Sim-
ilarly, a decrease in 2GSH/GSSG ratio is also an indicator of increased
risk for oxidative stress. Thus, the absence of any increased ROS con-
tent in FH+ myotubes differentiated in HGI could be the result of
these increased anti-oxidative stress defenses. The fact that FH+
myotubes showed a trend for increased oxidative stress defenses, even
in standard medium conditions (LGI) suggests that these myotubes
need increased oxidative stress defenses to maintain low levels of
oxidative stress.
5. Conclusions
In summary, our results reveal an increased mtDNA content, but no
difference in mitochondrial protein expression in insulin-sensitive
myotubes derived from offspring of T2DMpatients. Oxidative stress de-
fenses (proton leak, SOD2 expression, 2GSH/GSSG) tended to be higher
in FH+myotubes,while ROS contentwas not different (LGI conditions)
1632 C. Aguer et al. / Biochimica et Biophysica Acta 1832 (2013) 1624–1633or decreased (HGI conditions) in thesemyotubes compared tomatched
control myotubes. As a result of higher proton leak, mitochondrial
membrane potential and ATP content were lower in FH+ compared
to FH−myotubes. These ﬁndings indicate that FH+ myotubes appear
to need increased oxidative stress defenses in order to maintain a low
level of ROS and avoid oxidative damage. Furthermore, elevated state
4 respiration precedes the development of insulin resistance indicating
that mitochondrial dysfunction could thus be one of the early signs of
muscle insulin resistance development. If our in vitro results are trans-
latable to the in vivo conditions, our results suggest that, in the develop-
ment of muscle insulin resistance, there is an initial compensatory
phase characterized by increased mtDNA and oxidative stress defense
mechanisms that provisionally protect against thedevelopment of insu-
lin resistance.
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